Core Insights - Adial Pharmaceuticals has appointed Tony Goodman as Chief Operating Officer to oversee strategic growth initiatives, including clinical development and commercialization planning for AD04, a treatment for alcohol use disorder (AUD) [1][2] - The company is advancing its AD04 clinical program and preparing for potential commercialization, leveraging Goodman's extensive experience in the biopharmaceutical industry, particularly in addiction treatment [2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead product AD04 being a serotonin-3 receptor antagonist aimed at treating AUD [3] - AD04 has shown promising results in the ONWARD™ Phase 3 clinical trial, particularly in reducing heavy drinking among patients with specific genetic profiles, which represent about one-third of the AUD population [3] Leadership Background - Tony Goodman has over 23 years of experience in the pharmaceutical and biotech industries, previously serving as Chief Business Development Officer at Indivior PLC, where he contributed to significant revenue growth in the addiction market [2][3] - Goodman is also the founder of The Keswick Group LLC, a strategic advisory firm, and has held various leadership roles in commercial development and strategic planning [2]
Adial Announces Appointment of Tony Goodman as Chief Operating Officer